ASX - By Stock
|
PAR |
Re:
General OA media and info
|
|
Axlerod
|
670 |
255K |
18 |
31/01/24 |
31/01/24 |
ASX - By Stock
|
670
|
255K
|
18
|
|
ASX - By Stock
|
PAR |
Re:
General OA media and info
|
|
Axlerod
|
670 |
255K |
35 |
23/11/23 |
23/11/23 |
ASX - By Stock
|
670
|
255K
|
35
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Trading Halt
|
|
Axlerod
|
71 |
27K |
3 |
19/10/23 |
19/10/23 |
ASX - By Stock
|
71
|
27K
|
3
|
|
ASX - By Stock
|
PAR |
Re:
4m short sold
|
|
Axlerod
|
21 |
11K |
4 |
03/08/23 |
03/08/23 |
ASX - By Stock
|
21
|
11K
|
4
|
|
ASX - By Stock
|
PAR |
Re:
Perspective
|
|
Axlerod
|
9 |
3.4K |
14 |
28/03/23 |
28/03/23 |
ASX - By Stock
|
9
|
3.4K
|
14
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Axlerod
|
4.1K |
1.9M |
32 |
01/03/23 |
01/03/23 |
ASX - By Stock
|
4.1K
|
1.9M
|
32
|
|
ASX - By Stock
|
PAR |
Re:
Resolution of lumbar bone marrow oedema
|
|
Axlerod
|
76 |
35K |
5 |
18/01/23 |
18/01/23 |
ASX - By Stock
|
76
|
35K
|
5
|
|
ASX - By Stock
|
PAR |
Re:
AGM Lunch
|
|
Axlerod
|
15 |
7.9K |
4 |
24/11/22 |
24/11/22 |
ASX - By Stock
|
15
|
7.9K
|
4
|
|
ASX - By Stock
|
PAR |
AGM Lunch
|
|
Axlerod
|
15 |
7.9K |
5 |
10/11/22 |
10/11/22 |
ASX - By Stock
|
15
|
7.9K
|
5
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Axlerod
|
4.1K |
1.9M |
33 |
04/10/22 |
04/10/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
33
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Axlerod
|
4.1K |
1.9M |
12 |
27/09/22 |
27/09/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
12
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Axlerod
|
4.1K |
1.9M |
22 |
21/09/22 |
21/09/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
22
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Axlerod
|
4.1K |
1.9M |
25 |
08/09/22 |
08/09/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
25
|
|
ASX - By Stock
|
PAR |
Re:
The novel drug - A DMOAD approach
|
|
Axlerod
|
36 |
14K |
0 |
16/08/22 |
16/08/22 |
ASX - By Stock
|
36
|
14K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
The novel drug - A DMOAD approach
|
|
Axlerod
|
36 |
14K |
2 |
15/08/22 |
15/08/22 |
ASX - By Stock
|
36
|
14K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Axlerod
|
4.1K |
1.9M |
63 |
15/08/22 |
15/08/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
63
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Trading Halt
|
|
Axlerod
|
276 |
106K |
2 |
13/08/22 |
13/08/22 |
ASX - By Stock
|
276
|
106K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Trading Halt
|
|
Axlerod
|
276 |
106K |
4 |
12/08/22 |
12/08/22 |
ASX - By Stock
|
276
|
106K
|
4
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Trading Halt
|
|
Axlerod
|
276 |
106K |
0 |
12/08/22 |
12/08/22 |
ASX - By Stock
|
276
|
106K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Trading Halt
|
|
Axlerod
|
276 |
106K |
0 |
11/08/22 |
11/08/22 |
ASX - By Stock
|
276
|
106K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Trading Halt
|
|
Axlerod
|
276 |
106K |
13 |
11/08/22 |
11/08/22 |
ASX - By Stock
|
276
|
106K
|
13
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Axlerod
|
4.1K |
1.9M |
15 |
08/08/22 |
08/08/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
15
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Axlerod
|
4.1K |
1.9M |
28 |
03/08/22 |
03/08/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
28
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Axlerod
|
4.1K |
1.9M |
30 |
01/08/22 |
01/08/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
30
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Axlerod
|
4.1K |
1.9M |
22 |
28/07/22 |
28/07/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
22
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Investor Webinar
|
|
Axlerod
|
103 |
44K |
9 |
20/07/22 |
20/07/22 |
ASX - By Stock
|
103
|
44K
|
9
|
|
ASX - By Stock
|
PAR |
Re:
Capital Funding – Paul Rennie and Marco Polizzi please read
|
|
Axlerod
|
7 |
3.3K |
11 |
18/07/22 |
18/07/22 |
ASX - By Stock
|
7
|
3.3K
|
11
|
|
ASX - By Stock
|
PAR |
Capital Funding – Paul Rennie and Marco Polizzi please read
|
|
Axlerod
|
7 |
3.3K |
23 |
18/07/22 |
18/07/22 |
ASX - By Stock
|
7
|
3.3K
|
23
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Application for quotation of securities - PAR
|
|
Axlerod
|
27 |
8.6K |
2 |
14/07/22 |
14/07/22 |
ASX - By Stock
|
27
|
8.6K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Application for quotation of securities - PAR
|
|
Axlerod
|
27 |
8.6K |
2 |
14/07/22 |
14/07/22 |
ASX - By Stock
|
27
|
8.6K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Application for quotation of securities - PAR
|
|
Axlerod
|
27 |
8.6K |
0 |
14/07/22 |
14/07/22 |
ASX - By Stock
|
27
|
8.6K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Axlerod
|
4.1K |
1.9M |
8 |
13/07/22 |
13/07/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
8
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Application for quotation of securities - PAR
|
|
Axlerod
|
27 |
8.6K |
2 |
13/07/22 |
13/07/22 |
ASX - By Stock
|
27
|
8.6K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Axlerod
|
4.1K |
1.9M |
12 |
20/06/22 |
20/06/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
12
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Axlerod
|
4.1K |
1.9M |
9 |
08/06/22 |
08/06/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
9
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Axlerod
|
4.1K |
1.9M |
17 |
31/05/22 |
31/05/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
17
|
|
ASX - By Stock
|
PAR |
Re:
Resolution of lumbar bone marrow oedema
|
|
Axlerod
|
76 |
35K |
7 |
12/05/22 |
12/05/22 |
ASX - By Stock
|
76
|
35K
|
7
|
|
ASX - By Stock
|
PAR |
Re:
PARate Day Share Price 2022
|
|
Axlerod
|
116 |
51K |
3 |
12/05/22 |
12/05/22 |
ASX - By Stock
|
116
|
51K
|
3
|
|
ASX - By Stock
|
PAR |
Re:
Resolution of lumbar bone marrow oedema
|
|
Axlerod
|
76 |
35K |
5 |
11/05/22 |
11/05/22 |
ASX - By Stock
|
76
|
35K
|
5
|
|
ASX - By Stock
|
PAR |
Re:
Resolution of lumbar bone marrow oedema
|
|
Axlerod
|
76 |
35K |
6 |
11/05/22 |
11/05/22 |
ASX - By Stock
|
76
|
35K
|
6
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Axlerod
|
4.1K |
1.9M |
35 |
03/05/22 |
03/05/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
35
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Axlerod
|
4.1K |
1.9M |
18 |
12/04/22 |
12/04/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
18
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Axlerod
|
4.1K |
1.9M |
18 |
09/03/22 |
09/03/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
18
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Axlerod
|
4.1K |
1.9M |
3 |
09/03/22 |
09/03/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
3
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Axlerod
|
4.1K |
1.9M |
2 |
09/03/22 |
09/03/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
2
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Axlerod
|
4.1K |
1.9M |
5 |
07/03/22 |
07/03/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
5
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Axlerod
|
4.1K |
1.9M |
35 |
23/11/21 |
23/11/21 |
ASX - By Stock
|
4.1K
|
1.9M
|
35
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Axlerod
|
4.1K |
1.9M |
17 |
28/10/21 |
28/10/21 |
ASX - By Stock
|
4.1K
|
1.9M
|
17
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Axlerod
|
4.1K |
1.9M |
17 |
13/10/21 |
13/10/21 |
ASX - By Stock
|
4.1K
|
1.9M
|
17
|
|
ASX - By Stock
|
MSB |
Re:
Regulatory Pathways - where we stand with the FDA
|
|
Axlerod
|
74 |
26K |
1 |
25/08/21 |
25/08/21 |
ASX - By Stock
|
74
|
26K
|
1
|
|